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Comparison of two human immunodeficiency virus (HIV) RNA
surrogate assays to the standard HIV RNA assay
Abstract
Human immunodeficiency virus (HIV) RNA testing is the gold standard for monitoring antiretroviral
therapy in HIV-infected patients. However, equipment and reagent costs preclude widespread use of the
assay in resource-limited settings. The Perkin-Elmer Ultrasensitive p24 assay and the Cavidi Exavir
Load assay both offer potentially simpler, less costly technologies for monitoring viral load. These
assays were compared to the Roche Amplicor HIV-1 Monitor Test, v1.5, using panels of clinical
samples (subtype B) from HIV-positive subjects and HIV-spiked samples (subtypes A, C, D,
CRF_01AE, CRF_02AG, and F). The Ultrasensitive p24 assay detected 100% of the spiked samples
with virus loads of >250,000 copies/ml and 61% of the clinical samples with virus loads of 219 to
288,850 copies/ml. Detection rates were improved substantially if an external lysis buffer was added to
the procedure. The Cavidi assay detected 54 to 100% of spiked samples with virus loads >10,000
copies/ml and 68% of the clinical samples. These detection rates were also greatly improved with a
newly implemented version of this kit. Coefficients of variation demonstrate good reproducibility for
each of these kits. The results from the Cavidi v1.0, Cavidi v2.0, and Perkin-Elmer, and the
Perkin-Elmer Plus external buffers all correlated well with the results from the Roche Monitor Test (r =
0.83 to 0.96, r = 0.84 to 0.99, r = 0.58 to 0.67, and r = 0.59 to 0.95, respectively). Thus, the use of these
two assays for monitoring patients, together with less-frequent confirmation testing, offers a feasible
alternative to frequent HIV RNA testing in resource-limited settings.
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Human immunodeficiency virus (HIV) RNA testing is the gold standard for monitoring antiretroviral
therapy in HIV-infected patients. However, equipment and reagent costs preclude widespread use of the assay
in resource-limited settings. The Perkin-Elmer Ultrasensitive p24 assay and the Cavidi Exavir Load assay both
offer potentially simpler, less costly technologies for monitoring viral load. These assays were compared to the
Roche Amplicor HIV-1 Monitor Test, v1.5, using panels of clinical samples (subtype B) from HIV-positive
subjects and HIV-spiked samples (subtypes A, C, D, CRF_01AE, CRF_02AG, and F). The Ultrasensitive p24
assay detected 100% of the spiked samples with virus loads of >250,000copies/ml and 61% of the clinical
samples with virus loads of 219 to 288,850 copies/ml. Detection rates were improved substantially if an external
lysis buffer was added to the procedure. The Cavidi assay detected 54 to 100% of spiked samples with virus
loads >10,000 copies/ml and 68% of the clinical samples. These detection rates were also greatly improved with
a newly implemented version of this kit. Coefficients of variation demonstrate good reproducibility for each of
these kits. The results from the Cavidi v1.0, Cavidi v2.0, and Perkin-Elmer, and the Perkin-Elmer Plus external
buffers all correlated well with the results from the Roche Monitor Test (r ! 0.83 to 0.96, r ! 0.84 to 0.99, r
! 0.58 to 0.67, and r ! 0.59 to 0.95, respectively). Thus, the use of these two assays for monitoring patients,
together with less-frequent confirmation testing, offers a feasible alternative to frequent HIV RNA testing in
resource-limited settings.
The human immunodeficiency virus (HIV) pandemic has
affected countries worldwide, but the impact on resource-lim-
ited countries has been especially devastating. Pressure to
lower the cost of antiretroviral therapies (ART) has been crit-
ical in fighting this battle. The current challenge is to identify
simplified assays for monitoring patients on ART that are less
expensive and less technically demanding with respect to facil-
ities and instrumentation (6, 12). In the past, the compromise
for using simplified methods has often been reduced sensitivity
or poor correlation with the gold standards used in industrial-
ized settings (4, 10). We compare here two commercially avail-
able kits that measure HIV-specific proteins, p24 and reverse
transcriptase (RT), respectively, and utilize simpler technolo-
gies to perform the tests. The first method is the Ultrasensitive
HIV p24 enzyme-linked immunosorbent assay (ELISA; HIV-1
p24 ELISA plus the ELAST ELISA Amplification System;
Perkin-Elmer Life Sciences, Inc.), and the second is the RT
assay (Exavir Load Assay; Cavidi Tech AB, Sweden). Both kits
offer less expensive alternatives for detecting HIV.
For the Ultrasensitive p24 assay, a standard ELISA format is
used for the capture and detection of HIV p24 coupled with a
specific signal amplification to increase the assay sensitivity.
Heat denaturation of the plasma prior to binding in the ELISA
step helps to dissociate immune complexes and denature the
antibodies (24) so that they no longer compete for binding to
the p24 antigen, a phenomenon that has plagued prior versions
of this assay (10, 19, 25). The assay also adds a kinetic readout
using the Quanti-Kin Detection System Software that was de-
veloped and validated in O. E. Varnier’s laboratory (8) to
increase the linear range of the assay. HIV p24 concentrations
are reported as femtograms of HIV-1 p24/ml of plasma
(R.I.L.A.B., S.r.l., Genoa, Italy).
For the RT assay (Cavidi), the RT enzyme is separated from
the virus particle using a solid-phase extraction manifold, and
the amount of RT enzyme is quantified using a functional assay
whereby the RT incorporates bromodeoxyuridine (BrdU)
monophosphate into DNA using a poly(A) template bound to
a 96-well plate (3, 16). BrdU is then quantified spectrophoto-
metrically using anti-BrdU conjugated to alkaline phosphatase,
followed by the addition of its substrate. The RT activity in the
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unknown sample is compared to that of a recombinant RT
enzyme standard with a known concentration. The extrapo-
lated result is reported as fg of RT/ml of plasma or as HIV-1
RNA equivalents/ml based on a conversion factor supplied by
the manufacturer. The assay has undergone revisions (17) to
improve sensitivity and results for both versions of the kit are
reported here.
We sought here to demonstrate the potential utility of mea-
suring HIV p24 or RT activity in plasma by comparing detec-
tion rates and sensitivity and correlating the surrogate marker
with HIV RNA detection.
(These data were presented in part as a poster on 14 to 17
September 2003 at the 43rd Annual Interscience Conference
on Antimicrobial Agents and Chemotherapy Meeting, Chi-
cago, Ill. [control #3803].)
MATERIALS AND METHODS
Specimens. The Virology Quality Assessment (VQA) Program created three
panels to evaluate the RT (Cavidi) and the Ultrasensitive p24 (Perkin-Elmer)
assays (Table 1). The panels were tested in multiple laboratories (Table 2). The
first panel consisted of replicates that were prepared by seeding a well-charac-
terized VQA HIV-1 subtype B stock into sodium citrate-treated HIV-seroneg-
ative plasma at defined concentrations (39). The panel was tested by the VQA
and University of North Carolina at Chapel Hill (UNC) laboratories using the
RT assays (Cavidi v1.0 and v2.0), the Ultrasensitive p24 kit (Perkin-Elmer, using
kit lysis buffer), a “modified” version of the p24 kit utilizing an external lysis
buffer (EB, kindly provided by Jorg Schupbach), and the HIV RT-PCR assay
(Roche). Viral loads for each member of this panel were determined by taking
the median of the data obtained from the HIV RT-PCR assays (Roche).
The second panel consisted of plasma from 18 HIV-infected donors enrolled
in the VQA donor program (subtype B HIV) and stocks of the NED panel (11)
seeded into HIV-seronegative plasma (HIV subtypes A, C, D, CRF_01AE,
CRF_02AG, and F). Clinical specimens were included in panel 2 to provide
testing with samples that could contribute both virion-associated and non-virion-
associated p24 antigen and help to clarify how these two components affect the
detection rate of each assay. Spiked samples were used for non-B subtypes due
to a lack of available clinical specimens. Eight laboratories tested the second
panel one to five times per kit (Table 2). The VQA and UNC laboratories tested
TABLE 1. Panel configurationa
Panel ID HIV subtype Nominal concn
b
(RNA cp/ml) Sample type
No. of replicates/
Cavidi/PE panelc
No. of
replicates/Roche
paneld
1 B 0 Seronegative plasma 2 2
B 500 Spiked 5 4
B 1,000 Spiked 5 4
B 2,000 Spiked 5 3
B 10,000 Spiked 4 3
B 50,000 Spiked 4 2
B 250,000 Spiked 3 3
B 750,000 Spiked 4 3
2g A 20,000 Spiked 2 2
B NAf Clinicale 1 1
C 20,000 Spiked 2 2
D 20,000 Spiked 1 1
AE 20,000 Spiked 3 3
F 20,000 Spiked 1 1
NA NA Seronegative plasma 3 3
3 B 0 Seronegative plasma 4 NA
B 100 Spiked 6 NA
B 400 Spiked 6 NA
B 1,000 Spiked 5 NA
B 2,000 Spiked 5 NA
B 6,000 Spiked 4 NA
B 10,000 Spiked 2 NA
a Spiked panels consist of stock virus seeded into seronegative plasma. Clinical samples consist of plasma samples collected from HIV-infected donors.
b The expected value obtained from serial dilution of a stock virus into HIV-seronegative plasma. cp, copies.
c Cavidi, RT assays (v1.0 and v2.0); PE, Ultrasensitive p24 assays (Perkin-Elmer and Perkin-Elmer ! EB).
d Roche panels had fewer replicates to accommodate smaller assay run size.
e Clinical samples were collected from 18 different donors (specimens from different dates were collected from 2 donors), and spiked samples were generated from
viral stocks.
f NA, not applicable.
g For panel, the last column of this table indicates the number of samples/replicates/Roche panel.
TABLE 2. Participating laboratories and number of panels assayed
per laboratory and per kit
Panel Laboratory
No. of panels assayed per laboratory and per kit
Cavidi v1.0 Cavidi v2.0 PE PE ! EB Roche
1 VQA 3 3 3 3 4
UNC 3 NDa 3 3 4
2 Australia 2 ND ND ND ND
CDC ND ND 1 ND ND
Cavidi 1 ND ND ND ND
Switzerland ND ND ND 1 ND
Italy ND ND 1 ND ND
South
Africa
1 ND ND ND ND
UNC 3 ND 3 3 ND
VQA 5 3 3 3 3
3 VQA ND 3 ND ND ND
a ND, testing not done by this laboratory for this particular assay.
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the panel using both buffers with the Ultrasensitive p24 (Perkin-Elmer) and the
v1.0 RT assay (Cavidi). The remaining laboratories tested the panel once using
only one of the assays. Viral loads for this panel ranged from 2.34 to 5.46 log10
HIV RNA copies/ml as defined by triplicate testing performed by the VQA
laboratories using the HIV RT-PCR assay (Roche).
The third panel consisted of spiked samples (subtype B HIV). This panel was
designed to evaluate the improved sensitivity in the newly enhanced RT assay
(Cavidi, v2.0). The range in viral load for this panel was 0 to 10,000 HIV RNA
copies/ml with an emphasis on replicates at the low end (100 to 6,000 HIV RNA
copies/ml). Testing was performed by the VQA only using the v2.0 RT assay
(Cavidi).
Roche Amplicor HIV-1 Monitor Test, v1.5. HIV RNA testing was performed
as defined in the package insert. For the standard extraction method, virus from
0.2 ml of plasma was lysed in the kit lysis buffer and the HIV RNA was precip-
itated using isopropanol and pelleted by centrifugation. After being washed with
ethanol, the RNA was resuspended in the kit dilution buffer. Extracted RNA was
amplified and detected according to the manufacturer’s instructions, and results
were reported as HIV RNA copies/ml (or log10 converted results). The equip-
ment that is necessary to perform the Roche Amplicor Monitor Test is listed in
Table 3. The estimated cost for this equipment is $13,200 (U.S. dollars).
Cavidi ExaVirLoad assay. Samples tested with the RT assay (Cavidi) were
handled according to the manufacturer’s directions. For v1.0, the RT from 1 ml
of plasma was treated with ion-exchange gel (16) to help facilitate capture using
a vacuum driven solid-phase extraction manifold provided by the manufacturer
for use with their kit. After the virus particles were washed with kit wash buffer
solution, the viral particles were lysed with the kit lysis buffer and the RT-
containing eluate was collected. The extracted RT enzyme was loaded into a
poly(A)-coated 96-well plate in 2 volumes (15 and 75 "l). A recombinant RT
enzyme, which was provided in the kit for generating the standard curve, was also
diluted and added to the plate in 2 volumes. Buffers containing reaction com-
ponents were added to the plate, followed by incubation at 33°C overnight. After
a washing step, the plate was developed colorimetrically and read on a spectro-
photometer. The results were reported as fg of HIV RT/ml of plasma and as HIV
RNA equivalents/ml of plasma (only HIV RNA equivalent results are presented
in this study).
Version 2.0 of the RT assay (Cavidi) was modified to improve assay sensitivity
(17). Briefly, the virus particles from 1 ml of plasma were coated, captured, and
lysed in 330 "l of lysis buffer instead of 600 "l of buffer to concentrate the RT
in the eluate; additionally, more RT (from the samples and standards) was added
to the 96-well plate (30 and 150 "l of eluate instead of 15 and 75 "l, respectively).
Finally, in an attempt to streamline and improve linearity of the assay, day 2 was
a day of extended incubation rather than washing and labeling, and day 3 was
used for the detection of the assay. Even though the assay still took 3 days, day
2 did not require any hands-on activity. The equipment that is necessary to
perform the Cavidi Exavir Load Assay is listed in Table 3. The estimated cost for
this equipment is $8,300 (U.S. dollars).
Perkin-Elmer HIV-1 p24 ELISA plus the ELAST ELISA Amplification Sys-
tem. The Ultrasensitive p24 assay (Perkin-Elmer) was performed according to
the manufacturer’s instructions using the kit lysis buffer. Briefly, the sample (50
"l of plasma) was lysed with 250 "l of prediluted kit lysis buffer, heated at 100°C
for 5 min, and cooled to room temperature. A volume of 250 "l of specimen,
control, or standard was then added to the respective wells of a 96-well plate. The
plate was incubated at 4°C overnight and then washed in an automated plate
washer. The captured p24 antigen was labeled with a biotinylated anti-p24
antibody, followed by a streptavidin-horseradish peroxidase treatment step. The
biotinyl-tyramide reagent (provided in the ELAST kit) was used to “amplify” the
streptavidin-coated bound antigen and was followed by a second streptavidin-
horseradish peroxidase step that was then developed colorimetrically and read
kinetically for 10 min, followed by a final reading after 30 min when the reaction
was stopped with concentrated acid. Quantitative results were reported based on
the algorithms incorporated into the p24 assay Quanti-Kin software.
The modified version (Perkin-Elmer plus EB) of this assay was performed
according to the manufacturer’s instructions, with one deviation. The specimen
(50 "l) was first incubated with 25 "l of the external buffer (30 mM Tris-HCl [pH
7.2], 450 mM NaCl, 1.5% Triton X-100, 1.5% deoxycholic acid [sodium salt],
0.3% sodium dodecyl sulfate, 10 mM EDTA) at room temperature for 10 min
(26). This sample was then treated with 225 "l of prediluted kit lysis buffer and
heat denatured as described above. Quantitative results were also reported based
on the algorithms incorporated into the p24 assay Quanti-Kin software. The
equipment that is necessary to perform the Perkin-Elmer Ultrasensitive p24 test
is listed in Table 3. The estimated cost for this equipment is $6,800 (U.S. dollars).
Statistics. Detection rates were based on the kit-defined limits. For the RT
assay (Cavidi) and the Ultrasensitive p24 assay (Perkin-Elmer), no limit of
detection is set, but instead each assay’s limit of detection is defined based on the
combined performance of negative or background specimens and the standard
curve. The RT-PCR assay (Roche) limit of detection is 400 copies HIV RNA/ml.
Comparisons of reproducibility were based on coefficients of variation (CVs)
because the assays measure different analytes. The mean and standard deviation
was estimated from a model that allowed for left censoring where some of the
results were below the limit of detection of an assay. A CV was calculated only
if at least two positive results were obtained at a given concentration because
unbiased estimates of the mean and standard deviation could not be obtained
with fewer than two. The CVs for panel 1 were based on the intra-assay standard
deviation.
Rank correlations were calculated for each panel in an attempt to provide an
estimate of the relationship between the median log10 results obtained with the
RT (Cavidi v1.0 and v2.0) assays or the Ultrasensitive p24 (Perkin-Elmer and
Perkin-Elmer ! EB) assays and the Roche assay or nominal concentrations. A
separate correlation was calculated for each run of each assay in each laboratory.
Negative samples were excluded from all analyses. The results that were below
the limit of detection of an assay were assigned a value of 1.0. On panels 1 and
3, results from the various assays were correlated with nominal concentrations,
but for panel 2 the results were correlated with the median RT-PCR (Roche)
result because it included clinical samples that did not have a corresponding
nominal concentration. On panel 1, correlations with nominal concentrations
were calculated for the Ultrasensitive p24 (Perkin-Elmer plus EB) for nominal
concentrations greater than 10,000 copies/ml and for the RT assay (Cavidi v1.0
and v2.0) and the RT-PCR assay (Roche) at all positive concentrations. The
results from the Ultrasensitive p24 (Perkin-Elmer) were excluded because pos-
itive results were only obtained at the two highest concentrations. On panel 2,
correlations were calculated for the Ultrasensitive p24 (Perkin-Elmer and Per-
kin-Elmer plus EB) and the RT assays (Cavidi v1.0 and v2.0). The table includes
minimum, median, and maximum correlations for each assay, as well as the
number of correlations calculated (i.e., the number of runs available).
RESULTS
Detection rates for panels 1 to 3 are presented in Table 4.
These panels were designed to be detectable by the standard
HIV RT-PCR (Roche) assay (#400 copies/ml). One clinical
sample in panel 2 had a median virus load of 219 copies/ml,
and one replicate of this sample was undetectable by the HIV
RT-PCR assay (the negative result was excluded from the
median calculation).
The Cavidi v1.0 RT assay detected 98% of the specimens in
panel 1 with virus loads of 10,000 copies/ml or greater, while
the improved RT assay (Cavidi v2.0) detected 100% of the
specimens in panel 1 with virus loads of 500 copies/ml or more.
For panel 2, the Cavidi v2.0 RT assay also outperformed the
TABLE 3. Estimated equipment cost by assay
Assay
Cost (U.S. $)
Thermal cycler Plate washer Plate reader Solid phaseextraction manifold Incubator Heat block
Total equipment
cost
HIV RNA 7,000 900 5,000 300 13,200
RT assay 5,000 3,000 300 8,300
Ultrasensitive p24 900 5,000 300 600 6,800
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v1.0 assay. Detection rates improved from 9 to 100% for the
v1.0 assay to 27 to 100% for the v2.0 assay. For panel 3, the
Cavidi v2.0 RT assay detected 100% of the specimens with
virus loads of 400 copies/ml or greater.
For panel 1, the Ultrasensitive p24 assay (Perkin-Elmer)
detected 100% of the specimens with virus loads of 250,000
copies/ml or greater; the addition of the external buffer in-
creased the detection rate to 100% for samples with virus loads
of 50,000 copies/ml or greater. Detection rates for the Ultra-
sensitive p24 (Perkin-Elmer) assay were also improved in
panel 2, when the external buffer was included. Detection of
samples from panel 2 ranged from 0 to 86% for the Ultrasen-
sitive p24 assay, but improved to 66 to 99% when the external
buffer was used in the procedure. Better sensitivity was ob-
served in clinical specimens than in spiked samples, regardless
of the buffer used.
For panel 2, the combination of intra- and interassay varia-
tion was used because the absence of replication within the
panel prevented estimation of the intra-assay standard devia-
tion. For panel 1, median CVs were 31, 31, 27, 27, and 13% for
the RT-PCR (Roche), RT (Cavidi v1.0), RT (Cavidi v2.0),
Ultrasensitive p24 (Perkin-Elmer), and modified p24 (Perkin-
Elmer plus EB) assays, respectively. For panel 2, the median
CVs were 26, 26, 17, 18, and 57%.
Correlation values between RT-PCR (Roche) and nominal
concentrations were very good, indicating that the expected
virus load of the panel members was very close to that which
was obtained by RNA testing (Table 5). The Ultrasensitive p24
assay (Perkin-Elmer) gave reasonable correlation values with
HIV RNA concentration, but this correlation was improved
when an external buffer was used (Perkin-Elmer plus EB).
TABLE 4. Observed detection rates for panels 1, 2, and 3
Panel HIV subtype Nominal concn(HIV RNA copies/ml)
Median log10 HIV RNA
copies/ml (RT-PCR)a
% Detected (n)b
Cavidi
v1.0
Cavidi
v2.0 PE
PE !
EB Roche
1 B 0 UDc 0 (12) 0 (6) 0 (12) 0 (12) 0 (16)
B 500 732 37 (30) 100 (15) 0 (30) 0 (30) 100 (32)
B 1,000 1,185 33 (30) 100 (15) 0 (30) 0 (30) 100 (32)
B 2,000 2,182 60 (30) 100 (15) 0 (30) 0 (30) 100 (23)d
B 10,000 12,394 92 (24) 100 (12) 0 (24) 0 (24) 100 (24)
B 50,000 52,394 100 (24) 100 (12) 0 (24) 100 (24) 100 (16)
B 250,000 275,861 100 (18) 100 (9) 100 (18) 100 (18) 100 (24)
B 750,000 817,569 100 (24) 100 (12) 100 (24) 100 (24) 100 (22)e
2 A 20,000 30,768–40,585 100 (26) 100 (6) 0 (16) 86 (14) 100 (6)
B NAh 219–983 9 (65) 27 (15) 18 (40) 69 (35) 93 (15)
B NA 1,241–8,061 65 (65) 93 (15) 35 (40) 66 (35) 100 (15)
B NA 36,332–288,850 100 (143) 100 (33) 86 (88) 99 (77) 100 (33)
C 20,000 14,740–43,701 100 (26) 100 (6) 0 (16) 79 (14) 100 (6)
D 20,000 18,230 54 (13) 100 (3) 0 (8) 71 (7) 100 (3)
AE 20,000 32,245–50,167 79 (39) 100 (9) 0 (24) 86 (21) 100 (9)
F 20,000 33,910 100 (13) 100 (3) 0 (8) 86 (7) 100 (3)
NA NA UD 0 (39) 0 (8)d 0 (24) 0 (21) 0 (9)
3 B 0 NDf ND 0 (12) ND ND ND
B 100 ND ND 11 (18) ND ND ND
B 400 ND ND 100 (18) ND ND ND
B 1,000 ND ND 100 (13)g ND ND ND
B 2,000 ND ND 100 (15) ND ND ND
B 6,000 ND ND 100 (15) ND ND ND
B 10,000 ND ND 100 (6) ND ND ND
a Determined by replicate testing using the Standard Roche Monitor Test, v1.5.
b n includes replicate testing across laboratories. PE, Perkin-Elmer.
c UD, undetectable.
d One invalid sample result was excluded.
e Two invalid samples were excluded.
f ND, testing was not done.
g Two failed sample results were excluded.
h NA, not applicable.
TABLE 5. Rank correlation values provide an estimate of the
linear relationship between median log10 nominal concentrations or
RNA copies/ml and Ultrasensitive p24 or RT assays
Panel Kita No. ofruns
r
Min Median Max
1 PE ! EB 6 0.94 0.94 0.95
Cavidi v1.0 6 0.83 0.89 0.96
Cavidi v2.0 3 0.89 0.99 0.99
RT-PCR 8 0.94 0.97 0.99
2 Cavidi v1.0 13 0.86 0.93 0.95
Cavidi v2.0 3 0.84 0.95 0.96
PE 8 0.58 0.61 0.67
PE ! EB 7 0.59 0.74 0.76
3 Cavidi v2.0 3 0.98 0.98 0.98
a PE, Perkin-Elmer.
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Furthermore, better correlations between RT-PCR and Ultra-
sensitive p24 values were observed when panel members in-
cluded only spiked samples versus spiked and clinical samples.
The RT assays (Cavidi v1.0 and v2.0) correlated very well with
virus load and did not seem to vary if the panel included spiked
or clinical samples.
DISCUSSION
Monitoring HIV disease in resource-rich countries involves
extensive clinical testing (6, 12). HIV RNA testing by RT-PCR
and CD4 testing by flow cytometry are both used to track the
status of the viral infection and the progression of immune
destruction. Safety testing to monitor drug toxicities and gen-
eral health status and genotypic and phenotypic testing to
monitor individuals with failing regimens in order to detect the
emergence of drug resistance add to the burden of monitoring
patients. Although tight control of HIV infection has proven
beneficial in reducing mortality and morbidity in HIV-infected
individuals, cost restraints limit the testing that can be per-
formed in many of the countries where the burden of HIV
infection is greatest. Strategies need to be developed for less
intensive monitoring, while not compromising the outcome for
the patient.
The search for a simplified assay to measure HIV has iden-
tified two potential candidates. The first, the Ultrasensitive p24
(Perkin-Elmer) assay, measures the HIV-specific core protein,
which may be present as virion-associated or free p24 antigen,
although free p24 is mostly bound in immune complexes (25,
27). The correlation between p24 detection and HIV RNA or
CD4 cell counts has been evaluated in a number of studies.
Schupbach and others have demonstrated that the p24 is pre-
dictive of CD4 depletion (14, 28) and disease progression (14,
35), that it decreases when ART is initiated (2, 23, 29), and that
it correlates inversely with CD4 changes even when HIV RNA
is so low that it cannot be quantitated (30, 31). However,
disappointing results have also been reported using this kit (1,
21). Bonard et al. tested plasma samples from 14 patients
treated with highly active antiretroviral therapy, found weaker
changes in Ultrasensitive p24 antigen testing compared to HIV
RNA results, and questioned the reliability of this assay as an
RNA surrogate for clinical management of HIV-infected pa-
tients. Prado et al. demonstrated a lack of correlation between
HIV RNA and the Ultrasensitive p24 assay (Perkin-Elmer) for
monitoring patients undergoing a structured treatment inter-
ruption. Prado et al. found that discordance between HIV
RNA detection and p24 detection after viral rebound was 76%
of the treated patients and 49% of the naive patients enrolled
in the study. The discordance was attributed to the presence of
high-affinity immunoglobulins that interfered with the p24 as-
say detection. More recently, Schupbach et al. reported that
p24 antigen was detectable and remained relatively unchanged
during short STI (31). These contradictory findings demon-
strate the importance of using standardize methods in attempts
to compare assays and demonstrate clinical utility. The two
earlier studies utilized the Ultrasensitive p24 kits in absence of
the modified external buffer, while the third study included it.
Our data demonstrate that the modified buffer does impact the
sensitivity of the assay; fully optimized assays should be used
for future studies trying to demonstrate utility of this assay for
monitoring HIV disease progression.
The p24 data obtained in the current study need to be
interpreted carefully. The panels utilized contained two dis-
tinct types of samples, those that were spiked with well-char-
acterized virus and those that were obtained from HIV-in-
fected individuals. The reality is that clinical samples will
typically contain p24 that is both not virion associated and
virion associated. However, in attempting to evaluate the per-
formance of a particular assay there are benefits to using a
well-characterized specimen, including the ability to decipher
the contribution of immune-complexed versus virion-associ-
ated p24 antigen in the detection rates of this assay.
Limits of detection were quite high in samples where only
virion-associated p24 was present (i.e., HIV spiked samples). It
is estimated that 2,000 to 4,000 p24 Gag proteins are present in
each virion, so it would take 6,150 to 12,500 virus particles or
12,500 to 25,000 copies of viral RNA to detect 1 pg of p24
protein (5). Since the limit of detection of the modified p24
assay is approximately 6 pg/ml, it is not surprising that the
observed detection rate in spiked samples is approximately
100,000 copies/ml. When clinical samples were tested, the de-
tection rate appeared to be greatly improved, and this is pre-
sumed be due to the presence of non-virion-associated p24.
Since the contribution of this component may vary between
patients (4, 25) and change with disease progression (13, 14,
35), the impact on HIV monitoring is not fully understood and
explains the lower correlation with HIV RNA. HIV p24 de-
tection rates were improved with the use of the external buffer
(kindly provided by Jorg Schupbach), especially in HIV-spiked
samples, where only virion-associated proteins were present.
The improved sensitivity with spiked samples suggests that the
buffer may help to facilitate dissociation of the protein from
the virus particle. Although the added external buffer also
appeared to improve the detection of non-B subtypes, a more
likely explanation would be that improved detection of the
non-B subtype samples was due to improved assay sensitivity.
CV data demonstrate that comparable results were obtained
between laboratories with the p24 assay. Correlations between
the p24 assay and HIV RNA were lower when the kit buffer
was used (r $ 0.58 to 0.67) than when the external buffer was
used (r $ 0.59 to 0.95). Furthermore, correlations were higher
when only spiked samples were included. The correlations with
HIV RNA reported in this study were not different than those
reported (r$ 0.48 to 0.69) in other studies which did not utilize
the external buffer (20, 22). Respess et al. did document a
difference in correlation between untreated (r $ 0.69) and
treated (r $ 0.48) patients, similar to the difference noted in
this study between spiked and clinical specimens. This may be
attributed to the fact that treatment alters the presence of
virion-associated and non-virion-associated p24 antigen that is
available for detection. Although more data are need to dem-
onstrate the utility of the p24 assay for monitoring patients on
ART, preliminary data suggest that it may prove useful for
pediatric HIV diagnosis (15, 22, 37, 33) or diagnosis of acute
infection (20). The fact that a small sample volume is required
is especially attractive for pediatric diagnosis, and ongoing
studies are under way to evaluate the potential for using this
assay for detection of p24 in blood spots.
The second candidate to be considered as a surrogate for
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HIV RNA testing is the RT (Cavidi) assay. A number of
studies in Africa, Australia, and France have provided excel-
lent correlations between the RT and HIV RNA assays (3, 9,
34, 36). The fact that the assay only monitors virion-associated
RT contributes to this excellent correlation. In addition, the
assay could be useful in the detection of other lentiviruses (18),
including HIV-2, and the extracted RT may be used in the
Cavidi HIV Phenotype RT kit for evaluating resistance in
patients on anti-RT regimens (32, 38). The simplified equip-
ment, which includes a standard spectrophotometer, a vacuum
driven extraction manifold, and wash buckets for plate wash-
ing, make this assay especially attractive for resource-limited
urban and rural settings. The assay result may be reported as fg
of RT/ml of plasma, but the use of a conversion factor may be
used to convert the result into a more familiar readout of HIV
RNA equivalents/ml. While the utility of this assay for moni-
toring patients on ART has yet to be fully evaluated, the
roll-out of the v2.0 assay, with its improved sensitivity, should
have a major impact. A limiting factor of this assay is sample
volume. While a 1-ml plasma input is not problematic for
monitoring adult patients, it certainly may be problematic for
monitoring pediatric patients. Smaller sample volumes (down
to 0.25 ml) may be utilized; however, this reduces assay sensi-
tivity by the dilution factor involved (data from Cavidi).
The RT assay (Cavidi v1.0) showed good detection rates for
samples with viral loads of #10,000 copies/ml. The v2.0 assay
improved this detection limit to 400 copies/ml, which is com-
parable to that observed with the HIV RT-PCR assay (Roche)
routinely used in many industrialized countries. CV analyses
demonstrated comparable reproducibility between the RT and
RNA assays. Comparable results were also obtained between
the laboratories performing the testing, suggesting the assay is
quite robust. Higher CVs were noted in the v2.0 assay than in
the v1.0 assay. This was mainly observed in samples with lower
viral loads, a phenomenon that has also been noted in HIV
RNA assays for samples with viral loads near the limit of
detection (7). Correlation between HIV RNA (Roche) and the
RT (Cavidi) results were excellent for both versions of the kit
(r $ 0.83 to 0.99) and did not vary per panel. These results are
quite similar to those reported by other investigators (9, 34, 36)
using both versions of the RT assay (Cavidi). Preliminary stud-
ies involving non-B subtypes (34, 36), suggest that clades
CRF02_AG, C, and B are detected well with this assay, but
more studies are needed to substantiate these observations and
better define detection rates of other clades. Factors that could
affect detection rates include the presence of RT inhibitors or
resistance mutations in the RT gene. The data presented by
Greengrass et al. (9) suggest that the presence of non-nucleo-
side RT inhibitor-associated resistance mutations may reduce
the RT activity by 0.20 log10, but the presence or absence of
nucleoside RT inhibitor resistance mutations was not associ-
ated with RT activity. More data are needed to confirm this
observed effect on RT activity and its impact on monitoring
HIV-infected patients.
The benefits of using HIV RNA surrogates are assay sim-
plicity and cost reduction. While kit and reagent costs will vary
by country (RT-PCR $ $17 to $80, RT assay $ %$20, Ultra-
sensitive p24 $ $5 to $10), equipment requirements for the
HIV RNA surrogate assays are simpler and ca. 40 to 50% less
expensive. In addition, although HIV RNA assays require well-
developed infrastructures to ensure sterility and containment
of nucleic acids and amplified products, the HIV RNA surro-
gate assays have more simplistic requirements with respect to
facilities since nucleic acid extractions and amplification are
not part of the assay. Therefore, the use of an HIV RNA
surrogate assay to screen patients for drug efficacy and com-
pliance, followed by less-frequent confirmation testing with
molecular assays, may provide a useful strategy in resource-
poor settings. The two assays evaluated in this study offer
feasible RNA surrogates and should be considered for use in
this type of strategy.
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